Q1 Earnings Forecast for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD) – Research analysts at HC Wainwright issued their Q1 2027 EPS estimates for Invivyd in a research report issued on Tuesday, May 19th. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Invivyd’s Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.07) EPS and Q4 2027 earnings at ($0.05) EPS.

Invivyd (NASDAQ:IVVD) last announced its earnings results on Thursday, May 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.05). Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%.The business had revenue of $13.74 million during the quarter, compared to analyst estimates of $18.04 million.

Other research analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday. BTIG Research reiterated a “buy” rating and set a $10.00 target price on shares of Invivyd in a research report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a report on Wednesday, April 29th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Invivyd presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Invivyd Stock Performance

Invivyd stock opened at $1.04 on Wednesday. The business’s fifty day moving average is $1.49 and its two-hundred day moving average is $1.89. The firm has a market cap of $306.39 million, a P/E ratio of -3.35 and a beta of 0.71. Invivyd has a 52 week low of $0.48 and a 52 week high of $3.07.

Institutional Investors Weigh In On Invivyd

A number of hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP raised its holdings in Invivyd by 85.0% during the 3rd quarter. GSA Capital Partners LLP now owns 805,221 shares of the company’s stock worth $886,000 after buying an additional 369,891 shares during the period. SummitTX Capital L.P. bought a new stake in Invivyd during the 1st quarter worth about $37,000. Stempoint Capital LP boosted its position in Invivyd by 89.4% during the first quarter. Stempoint Capital LP now owns 1,874,546 shares of the company’s stock valued at $2,437,000 after purchasing an additional 884,724 shares during the last quarter. Eversept Partners LP boosted its holdings in shares of Invivyd by 6.4% in the 1st quarter. Eversept Partners LP now owns 2,276,349 shares of the company’s stock valued at $2,959,000 after buying an additional 136,219 shares during the last quarter. Finally, Rangeley Capital LLC acquired a new stake in Invivyd in the first quarter valued at $58,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.